Hypertension Clinical Trial
Official title:
A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study
Primary Endpoint: Quantify the hemodynamic changes in preeclampsia using the non-invasive
Nexfin device.
Secondary Endpoint: Determine if measurable hemodynamic changes are statistically correlated
with B-type natriuretic peptide (BNP) levels.
Hypertensive disorders of pregnancy including preeclampsia are the leading cause of pregnancy
related mortality in the United States. Timely and appropriate management of hypertensive
disorders of pregnancy is critical to prevent complications such as kidney failure, HELLP
syndrome, disseminated intravascular coagulation, placental abruption, intrauterine fetal
demise, intracranial bleed, coma and death. (HELLP syndrome is a group of symptoms that occur
inpregnant women who have: H -- hemolysis (the breakdown of red blood cells); EL -- elevated
liver enzymes; LP -- low platelet count.) Hypertensive disorders of pregnancy include
gestational hypertension (HTN), chronic HTN, preeclampsia and preexisting HTN with
superimposed preeclampsia.
Hypertensive disorders may also lead to significant maternal and/or fetal morbidity. Based on
the severity of the disease process and gestational age of the fetus, decision needs to be
made whether to proceed with immediate delivery or continue expectant management. Meanwhile,
maintenance of optimal blood pressure, blood volume, and cardiac output are recommended to
preserve placental perfusion and to prevent unfavorable maternal and/or fetal outcomes.
Previous studies have demonstrated blood flow differences in pregnancies complicated by
preeclampsia vs. healthy pregnant women evidenced by decreased arterial compliance, increased
systemic vascular resistance and after load, and changes in blood volume and cardiac output.
Additionally, various serum markers have been tried to identify women with preeclampsia.
B-Type natriuretic peptide (BNP) has been consistently shown to be elevated in preeclampsia,
and serves as a marker of heart function and intra vascular volume status.
Continuous hemodynamic monitoring may play a crucial role in timely management of these
patients with severe disease due to the dynamic nature of the disease process. Existing
methods are not preferred in pregnancy due to their invasive nature, and there is lack of
validated non-invasive means to provide real time information on various hemodynamic
parameters including cardiac output in these critically ill pregnant women.
Among new cardiac monitoring devices, the Nexfin device (BMEYE, Amsterdam, Netherlands) has
recently been introduced. Nexfin device is a device approved by the Food and Drug
Administration (FDA) as a non-invasive reliable method of continuous measuring arterial blood
pressure in pregnant women. However there are no preliminary data on preeclamptic patients
using this device. The standard of care is to use a sphygmomanometer for blood pressure
monitoring. Additionally there are no studies comparing the hemodynamics of healthy and
preeclamptic women using Nexfin device. Nexfin is thought to be superior over other available
non-invasive methods as it is a safe and a considerably accurate method. Nexfin provides
continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular
resistance and left ventricular contractility indices.
The study aims to determine if the non-invasive Nexfin device can be used to reliably
distinguish hemodynamics in preeclamptic vs. healthy pregnant women with singleton
pregnancies along with use of BNP levels. Investigators aim to recruit 33 healthy controls
and 33 subjects diagnosed with preeclampsia (mild and severe). Subject's systolic and
diastolic blood pressures will be measured using both the Nexfin device and a standard
sphygmomanometer (blood pressure meter). Additionally hemodynamic measure such as: heart
rate, cardiac output, stroke volume, systemic vascular resistance, and left ventricular
contractility will be recorded using the Nexfin device. Investigators will perform a blood
draw to measure BNP levels as an additional assessment of the hemodynamic changes in the two
groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |